AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue fell to $210.8M as hospital division revenue dropped 14.6% YoY, but a $52.3M reduction to contract services expense from the HaloMD amendment and CMS fee cut lifted net income to $96.3M.
Biggest Revenue Drivers
Hospital division$201.9M-14.6% YoY
Decrease primarily attributed to positive adjustments to variable consideration realized in 2025 as the Company experienced early success with the IDR process.
Population health management division$8.9M
Increase from $7.7M primarily due to increased members.
Biggest Revenue Drivers
Total revenue: $210.8M
Hospital division$201.9M-14.6% YoY
Decrease primarily attributed to positive adjustments to variable consideration realized in 2025 as the Company experienced early success with the IDR process.
Within Hospital division
Insurance96% of transaction price
Allocation of estimated transaction price by primary patient insurance classification; 97% in the prior-year quarter.
Self-pay2% of transaction price
Copays, deductibles and self-payment; 1% in the prior-year quarter.
Population health management division$8.9M
Increase from $7.7M primarily due to increased members.
Largest Expense Items
Payroll$42.8M
Up from $36.3M; higher payroll driven by increased wages to the physician LLCs, bonus payments and other payroll and benefits expenses.
General and administrative expenses$16.7M+$4.2M YoY
Includes executive management, accounting, human resources, corporate technology, insurance and professional fees.
Stock-based compensation$2.9M-$75.9M YoY
Lower expense on obligations for under-construction and ramping hospitals versus $78.7M in the prior-year quarter.
Contract services$1.1M
Down from $61.1M; reflects a $52.3M reduction from the HaloMD pay-on-collected amendment ($38.4M), revised service fee structure ($9.6M) and CMS fee cut ($4.3M).
Margins: Consolidated gross profit rose to $141.3M from $124.9M; hospital division gross profit increased 13.0% to $141.8M, primarily driven by lower total cost of arbitration of $(12.5)M versus $48.0M last year.
Watch Items from the Filing
The $52.3M contract services reduction was a change in estimate that increased net income by $43.0M and diluted EPS by $3.64 basic/$3.56 diluted this quarter.
Hospital revenue fell 14.6% and same-hospital revenue fell 12.1% even as patient visits rose 9.6%, reflecting prior-year IDR variable-consideration adjustments.
Company operates out-of-network with no negotiated rates; 96% of transaction price comes from insurance, and IDR estimation is highly subjective and volatile.
Pending securities class action and consolidated derivative suits seek unspecified damages; the Company cannot estimate potential financial impact.
Approximately 256,005 shares remain disputed by former doctor owners, including ABQ's 216,039 shares; trial is set for September 21, 2026.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
About Nutex Health Inc. (NUTX): stock profile, AI score and financials
Nutex Health Inc. (NUTX) stock profile, AI quality score, and SEC EDGAR financial data, a Industrials sector company. 13F Pro's AI-powered ranking engine scores NUTX at 74.3/100 on a composite quality score built from its SEC filings, placing it at rank #113 of 2,925 stocks — the top 5% of the AI-ranked universe. NUTX scores in the top quartile across revenue growth (96.4), balance sheet strength (96.0), free cash flow (86.3). Shareholder dilution risk is elevated at 13.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Nutex Health Inc. reports quarterly revenue of $210.8M, net income of $65.8M, an operating margin of 57.8%. Top institutional holders of NUTX by reported 13-F value include Pertento Partners LLP, BlackRock, AMERICAN CENTURY COMPANIES, based on the most recent SEC filings. NUTX trades on the Nasdaq exchange and files with the SEC under CIK 1479681. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NUTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nutex Health Inc. directly from SEC EDGAR.